Subscribe to Search results

A child with mild haemophilia had received commercial Factor VIII for a tooth extraction. This treatment "would not seem to be justified."

Published on:

A child born in 1980 (inferentially with severe haemophilia) "received a substantial amount of concentrate, the majority of it being commercial concentrate. The type of concentrate would have been dependant upon availability and treatment was standard." It was said that there was "Nothing atypical about treatment given to this Plaintiff."

Published on:

Another child with mild haemophilia was treated with what appeared to be NHS Factor 8 in late 1982 and commercial Factor 8 between March and July 1983.

Published on:

A patient with mild/moderate haemophilia was treated with concentrates for elective surgery. The notes lacked detail to identify products used but "Dr Martin's statement confirms that no distinction was made at Alder Hey Hospital in terms of which product to prefer" vs what was available.

Published on:

The Sheffield Centre treated its patients with a mix of NHS concentrates and commercial.

Published on:

There was a greater use of NHS concentrates than commercial, although a substantial amount of the latter (and a small amount of cryoprecipitate) was still used.

Published on:

Sheffield Centre switched to heat treated product occurred at the end of May 1984 along with three other centres.

Published on:

The vast majority of treatment was with commercial concentrates, with very little NHS concentrate used. This was likely to have reflected the use of heat-treated concentrates.

Published on:

An article was published in the Lancet regarding two patients treated with Armour heat-treated who developed NANB Hepatitis and a third treated with BPL's small pool heat-treated product..

Published on:

Dr Mitchell recollected that there was no patient at Leicester with mild or moderate Haemophilia A or Haemophilia B, or with von Willebrand disorder who tested positive.

Published on:

Dr Mitchell's policy in relation to adults with severe Haemophilia A was to adhere to one batch of one concentrate as much as possible. It took a year or so to implement this approach.

Published on:

When Dr Mitchell arrived at the Sheffield Centre, the majority of patients on home treatment were receiving commercial concentrate and he did not have the ability to switch them all over to NHS concentrates given the amount received.

Published on:

Whilst there were insufficient supplies so commercial concentrates were used. Dr Mitchell would have used more NHS product if it had been available.

Published on:

The approach at the Sheffield Centre for adults with severe Haemophilia A, was to treat them with NHS concentrates as much as possible.

Published on:

Local meetings with the Inquiry team

Published on:

Dr Mitchell did not experience difficulties with obtaining sufficient quantities of cryoprecipitate or with adverse reactions to cryoprecipitate.

Published on:

Dr Mitchell acknowledged that reactions could occur but did he not recall it being a major problem.

Published on:

Children with severe haemophilia, were to be treated with cryoprecipitate by the Sheffield Centre until they went onto home treatment.

Published on:

Dr Mitchell used DDAVP and tranexamic acid wherever possible for mild and moderate haemophilia and for von Willebrand disorder. This was largely successfully, although it was not always adequate for moderate patients.

Published on:

Dr Mitchell believed there to be a connection between the use of multi-donor factor concentrates and the development of liver disease.

Published on: